| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
DP-b99 chelates zinc and calcium ions selectively within cell membranes. Its unique mechanism involves partitioning into membranes where its chelating activity is activated, allowing it to buffer excessive intracellular calcium and zinc that contribute to excitotoxic neuronal death. By reducing calcium overload and zinc toxicity, it protects neurons from ischemic damage without affecting normal physiological ion homeostasis.
|
|---|---|
| ln Vitro |
In vitro, DP-b99 protects cultured neurons from excitotoxic injury induced by glutamate, NMDA, or zinc. It reduces calcium-induced mitochondrial dysfunction and prevents zinc-mediated neuronal death. Its membrane-selective chelation mechanism has been characterized in liposome and cell-based assays. Neuroprotection is assessed by MTT assay, LDH release, and caspase-3 activity.
|
| ln Vivo |
In vivo, DP-b99 demonstrates neuroprotective efficacy in animal models of stroke. In rodent models of transient or permanent middle cerebral artery occlusion, it reduces infarct volume and improves neurological outcomes. It also shows neuroprotective effects in models of traumatic brain injury and acute pancreatitis. The compound crosses the blood-brain barrier and reaches therapeutic concentrations in brain tissue.
|
| Enzyme Assay |
Ion chelation assays use fluorescent indicators such as Fura-2 for calcium or Newport Green for zinc. DP-b99 is added to liposomes or cell suspensions, and changes in fluorescence are measured to assess ion binding. Membrane partitioning is assessed by fluorescence spectroscopy using membrane probes. Selectivity for calcium and zinc over magnesium and iron is determined.
|
| Cell Assay |
Primary cortical or hippocampal neuronal cultures are used. Cells are treated with DP-b99 and exposed to excitotoxic stimuli (glutamate, NMDA, or zinc). Neuronal viability is measured by MTT assay, LDH release, or propidium iodide staining. Mitochondrial membrane potential is assessed using JC-1. Calcium and zinc levels are measured using fluorescent indicators.
|
| Animal Protocol |
Rodent stroke models include middle cerebral artery occlusion (MCAO) in rats and mice. DP-b99 is administered intravenously at doses ranging from 0.1-10 mg/kg before or after occlusion. Infarct volume is measured by TTC staining. Neurological function is assessed using modified neurological severity scores. Brain edema, blood-brain barrier integrity, and inflammatory markers are also evaluated.
|
| References |
|
| Additional Infomation |
DP-b99 is a newly developed lipophilic, cell-permeable BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid) derivative currently being developed as a neuroprotective agent for the potential treatment of nerve damage associated with stroke, head trauma, and coronary artery bypass grafting.
Pharmaceutical Indications It has been investigated for the treatment of stroke and traumatic brain injury. Mechanism of Action DP-b99 is an exploratory product rationally designed using D-Pharm's proprietary technology—Membrane Active Chelating Agents (MAC). Extensive evidence suggests that the redistribution of metal ions and disruption of metal ion homeostasis are key components of the stroke cell damage cascade. In the initial hours following a stroke, ion disturbances lead to excitatory cell damage; in the following days and weeks, ion disturbances lead to edema, inflammation, and cell death. DP-b99 is a novel neuroprotective method that achieves its effect by selectively modulating the homeostasis of calcium, zinc, copper, and iron near the cell membrane. |
| Molecular Formula |
C42H64N2O12
|
|---|---|
| Molecular Weight |
788.96376
|
| Exact Mass |
788.445
|
| CAS # |
222315-88-0
|
| PubChem CID |
9810955
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
864.8±65.0 °C at 760 mmHg
|
| Flash Point |
476.8±34.3 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.542
|
| LogP |
9.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
56
|
| Complexity |
969
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(CN(C1=CC=CC=C1OCCOC2=CC=CC=C2N(CC(OCCOCCCCCCCC)=O)CC(O)=O)CC(O)=O)OCCOCCCCCCCC
|
| InChi Key |
FTGBVHPWUIHWRH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C42H64N2O12/c1-3-5-7-9-11-17-23-51-25-27-55-41(49)33-43(31-39(45)46)35-19-13-15-21-37(35)53-29-30-54-38-22-16-14-20-36(38)44(32-40(47)48)34-42(50)56-28-26-52-24-18-12-10-8-6-4-2/h13-16,19-22H,3-12,17-18,23-34H2,1-2H3,(H,45,46)(H,47,48)
|
| Chemical Name |
2-[2-[2-[2-[carboxymethyl-[2-(2-octoxyethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-N-[2-(2-octoxyethoxy)-2-oxoethyl]anilino]acetic acid
|
| Synonyms |
DP-BAPTA-99; DP-b-99; DP-b 99
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~126.75 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.17 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2675 mL | 6.3375 mL | 12.6749 mL | |
| 5 mM | 0.2535 mL | 1.2675 mL | 2.5350 mL | |
| 10 mM | 0.1267 mL | 0.6337 mL | 1.2675 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
